top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • Jun 19
  • 2 min read

17/06/2026





UCB completed acquisition of Candid Therapeutics strengthening next generation immunology pipeline (Ref)


UCB announced the successful completion of its previously announced acquisition of Candid Therapeutics, a clinical-stage biotechnology company developing novel T-cell engager therapies for autoimmune and inflammatory diseases.


  • The acquisition strengthens UCB’s position as an innovator in immunology and expands its capabilities in next-generation biologics aimed at achieving immune reset.


  • It brings cizutamig (BCMA), Candid’s lead investigational asset, into UCB’s pipeline. The asset is currently being evaluated in multiple Phase 1 studies across a range of autoimmune diseases.


  • The total transaction is valued at up to US $2.2 billion, consisting of US $2 billion in upfront payments, plus up to US $200 million in potential future milestone payments.















Biogen expanded immunology pipeline with agreement to acquire RayThera (Ref)


Biogen and RayThera, announced that they had entered into a definitive agreement under which Biogen agreed to acquire RayThera Inc. for up to $1 billion, comprising an upfront payment and milestone-based payments tied to future clinical and regulatory achievements.


  • RayThera’s portfolio included multiple anti-inflammatory assets with potential applications across several immune-mediated diseases.


  • The lead candidate was expected to enter Phase 1 development in early Q3 2026.


  • Under the terms of the agreement, Biogen agreed to make an upfront payment to RayThera’s shareholders, who were also eligible to receive additional clinical and regulatory milestone payments for a total potential deal value of up to $1 billion.


  • The transaction remained subject to customary closing conditions, including regulatory approvals and was anticipated to close in Q3 2026.


  • Upon completion of the acquisition, Biogen was expected to lead the development, manufacturing, and global commercialization of the acquired assets.


bottom of page